AREV Life Sciences Global Corp.
AREVF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $49 | $255 | $191 | $195 |
| % Growth | -80.7% | 33.8% | -2.1% | – |
| Cost of Goods Sold | $20 | $70 | $0 | $66 |
| Gross Profit | $29 | $185 | $191 | $129 |
| % Margin | 59.3% | 72.6% | 100% | 66.3% |
| R&D Expenses | $84 | $148 | $128 | $1,149 |
| G&A Expenses | $986 | $1,441 | $562 | $1,964 |
| SG&A Expenses | $1,192 | $1,627 | $567 | $2,007 |
| Sales & Mktg Exp. | $206 | $186 | $5 | $43 |
| Other Operating Expenses | $16 | -$93 | -$52 | $66 |
| Operating Expenses | $1,292 | $1,682 | $643 | $3,221 |
| Operating Income | -$1,389 | -$1,497 | -$452 | -$3,026 |
| % Margin | -2,827.7% | -587% | -237.3% | -1,554.4% |
| Other Income/Exp. Net | -$181 | $507 | -$597 | -$167 |
| Pre-Tax Income | -$1,444 | -$990 | -$1,049 | -$3,193 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,444 | -$990 | -$1,049 | -$3,193 |
| % Margin | -2,940.4% | -388.4% | -550.4% | -1,640% |
| EPS | -0.048 | -0.036 | -0.068 | -0.36 |
| % Growth | -33% | 47.1% | 81% | – |
| EPS Diluted | -0.048 | -0.05 | -0.068 | -0.36 |
| Weighted Avg Shares Out | 30,075 | 27,469 | 15,361 | 8,956 |
| Weighted Avg Shares Out Dil | 30,075 | 27,469 | 15,361 | 8,956 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $6 | $46 | $59 | $73 |
| Depreciation & Amortization | $126 | $146 | $101 | $66 |
| EBITDA | -$1,311 | -$798 | -$500 | -$3,054 |
| % Margin | -2,668.7% | -312.8% | -262.3% | -1,568.7% |